Trailblazing a Path of Innovation

E. Selemon Asfaw is the Chief Financial Officer at OptumHealth, where he is responsible for leading the strategic financial direction for a portfolio of value-oriented health care delivery businesses. The portfolio offers direct physical and behavioral care to patients in a variety of settings and provides population health management to health plans and government agencies. Prior to this role, he was Director of Corporate Development at United Health Group and led M&A strategy and transaction execution on behalf of OptumHealth. Earlier in his career, Selemon was an Investment Banker with Goldman, Sachs & Co. in the Healthcare Group in New York City, where he spent most of his time covering Biopharmaceutical clients. He completed a Bachelor of Science in Business from the University of Minnesota and received his MBA from the Tuck School of Business at Dartmouth.

Jaewon Ryu, MD, JD, is Geisinger’s president and chief executive officer. He came to Geisinger as the Executive Vice President and Chief Medical Officer in 2016, and in that capacity, he has overseen all aspects of patient care at Geisinger, working to improve the quality, affordability, and experience of care delivered across the enterprise. Jaewon was previously at Humana, where he was President of integrated care delivery and responsible for Humana’s owned and joint ventured care delivery assets. Prior to Humana, he held various leadership roles at the University of Illinois Hospital & Health Sciences System, Kaiser Permanente (where he also practiced as an emergency medicine physician), and in government, at the Centers for Medicare and Medicaid Services, and as a White House Fellow at the Department of Veterans Affairs. He was also a practicing corporate healthcare attorney with the international firm McDermott, Will & Emery. Jaewon earned his BA degree from Yale University and his MD and JD from the University of Chicago. He completed his residency training in emergency medicine at Harbor-UCLA Medical Center.

Jo Carol Hiatt, MD, is the Vice President of Health Economics and Patient Value at the Medical Device Innovation Consortium (MDIC), where she will coordinate efforts between CMS, private payers, and advocacy groups to ultimately improve patient access to innovative medical devices at a reduced cost. She joins MDIC following her most recent tenure leading teams to review new technologies to inform evidence-based clinical technology options for Kaiser Permanente, one of America’s leading health care providers and nonprofit health plans. She is a general surgeon and partner emeritus with the Southern California Permanente Medical Group (SCPMG). Dr. Hiatt received her undergraduate degree from Stanford University and her medical degree from Duke University. She trained in general surgery at UCLA. In addition to her clinical degree, Dr. Hiatt received an MBA from UCLA’s Anderson School of Management.

Stephane Mouradian is Vice President of Business Development at Personalis, a leading immuno genomic company offering comprehensive testing for cancer patients. Previously, Stephane was Director of Business Development at Illumina, where he oversaw Illumina’s companion diagnostic partnerships in oncology, expansion of NIPT (Non Invasive Prenatal Testing), and Illumina’s venture investments in startups such as Twist (synthetic biology) and Boreal Genomics (liquid biopsy), for which he served as Illumina-appointed board observer. Prior to Illumina, Stephane was at Caliper Lifesciences for 15 years. He developed and launched several microfluidic DNA testing products that became standards in genomic laboratories today, and he led corporate development for Caliper. Stephane holds a Ph.D. in Analytical Chemistry from the University of Wisconsin, Madison, and a Master’s degree in Chemical Engineering from Strasbourg University, France.

Mike Rhodin recently retired from IBM after 33 years and 7 years as a corporate officer. Most recently, he was responsible for founding the IBM Watson business unit. Prior to that, Mike founded IBM’s solution units around their Smarter Planet initiatives. Mike began his professional career in 1984 when he joined IBM as a software engineer. He held various technology and management roles until 1997 when he moved to corporate headquarters and began his executive management career. He is a member of the Supervisory Board for TomTom, a member of the International Advisory Board for Santander, and a member of the National Advisory Board for the University of Michigan Computer Science program. Mike received a Bachelor of Science (Computer Science) degree from the University of Michigan and was recognized with an Alumni Merit Award in 2016. He was also recognized with an honorary Doctor of Science degree from Roanoke College for his contributions to the development of artificial intelligence systems.

Andrew Cleeland is the CEO of the Fogarty Institute and is a seasoned executive with 30 years in the medical device industry in both the private and public sectors. Prior to joining the Fogarty Institute, he was Vice President and General Manager of Medtronic’s (MDT:NYSE) Transcatheter Mitral Valve business following its 2015 acquisition of Twelve Inc., where he was President and CEO. Prior to Twelve, he was President and CEO of Ardian Inc., the pioneer of renal denervation for hypertension, heart failure, and other associated disorders, which was also acquired by Medtronic in 2011. He is currently Vice Chairman of The Foundry, the premier medical device incubator based in Menlo Park, CA. Andrew holds a Bachelor of Applied Science (Biophysics) from the Swinburne Institute of Technology.

Jeff Williams is CEO and Chairman of the Board at NeuMoDx Molecular and has more than 20 years of experience leading companies in life sciences and diagnostics. Jeff’s past experience includes serving as President & CEO of Accuri Cytometers, where he led the company through a period of rapid commercial growth to a sale to Becton Dickinson in March 2011 for $205 million. Prior to Accuri, Jeff was President and CEO of HandyLab, Inc., a clinical diagnostic company that was acquired by Becton Dickinson in November 2009 for $275 million. Jeff also served as President and CEO of Genomic Solutions Inc., a life science products company he co-founded in 1997, culminating in an IPO on NASDAQ in 2000 and a merger with Harvard Biosciences, Inc. in 2002. He received a BS in Biology from Alma College and an MBA from the Ross School of Business at the University of Michigan.

Nancy Schlichting is the retired Chief Executive Officer of Henry Ford Health System (HFHS), a nationally recognized $5.5 billion health care organization with 27,000 employees and recipient of the 2011 Malcolm Baldrige National Quality Award. She is credited with leading the health system through a dramatic financial turnaround and for award-winning patient safety, customer service, and diversity initiatives. Nancy joined HFHS in 1998 as its Senior Vice President and Chief Administrative Officer and was named President and CEO in 2003. Retiring in 2017, her career in health care administration spans over 35 years of experience in senior level executive positions. Nancy received her AB in Public Policy Studies, Magna Cum Laude from Duke University, and her MBA from Cornell University.

Bill Hawkins is the Former Chairman and CEO of Medtronic. He is currently advising private equity and venture capital groups and serving on multiple for-profit and non-profit boards. Bill was President and CEO of Immucor from Oct 2011 to July 2015. Prior to Immucor, he served as Chairman and CEO of Medtronic. Bill assumed the role of CEO in 2007 and became Chairman of the Board in 2008. He joined Medtronic in 2002 as SVP and President of Medtronic Vascular. Prior to Medtronic, he served as President and Chief Executive Officer of Novoste Corp. Nasdaq (NOVT). He was recently elected to the National Academy of Engineering and is an AIMBE Fellow. Bill is Lead Director at Immucor and is Vice Chair of the Board of the Duke University Health System. Bill received his bachelor’s degree in electrical and biomedical engineering from Duke University and an MBA from the University of Virginia.

Ray Huggenberger has served as a member of the Board of Directors of Inogen (Nasdaq: INGN) since 2008. Previously, Ray served as Inogen’s Chief Executive Officer from January 2008 to February 2017 and took the company public in 2014 at a market capitalization over $300 million. Prior to joining Inogen, Ray held various management positions with Sunrise Medical Inc., a global manufacturer and distributor of durable medical equipment, including President and COO. In addition to his role at Inogen, Ray currently serves on the Board of Directors of Wellfount, Ebb Therapeutics, and Clarify Medical and previously served on the Board of Directors of IYIA Technologies. Ray graduated from AKAD University in Rendsburg, Germany, with a degree in Economics and completed the Advanced Marketing Strategies Program at INSEAD, Fontainebleau, France.